These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 20215482

  • 21. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF, Grimm D, Bauer J, Wehland M, Wise P, Magnusson NE, Infanger M, Krüger M.
    Int J Mol Sci; 2017 Aug 10; 18(8):. PubMed ID: 28796163
    [Abstract] [Full Text] [Related]

  • 22. [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma].
    Gennigens C, Sautois B, Jerusalem G.
    Rev Med Liege; 2010 Apr 10; 65(4):212-6. PubMed ID: 20499824
    [Abstract] [Full Text] [Related]

  • 23. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK.
    Clin Genitourin Cancer; 2014 Aug 10; 12(4):262-9. PubMed ID: 24795159
    [Abstract] [Full Text] [Related]

  • 24. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R, Palazzo A, Trenta P, Mezi S, Pellegrino D, Naso G, Cortesi E.
    Am J Clin Oncol; 2014 Dec 10; 37(6):611-5. PubMed ID: 23388560
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
    Roca S, Quivy A, Gross-Goupil M, Bernhard JC, De Clermont H, Ravaud A.
    Acta Oncol; 2011 Oct 10; 50(7):1135-6. PubMed ID: 21726178
    [No Abstract] [Full Text] [Related]

  • 26. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH, Molina AM, Motzer RJ.
    Hematol Oncol Clin North Am; 2011 Aug 10; 25(4):835-52. PubMed ID: 21763970
    [Abstract] [Full Text] [Related]

  • 27. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
    Büchler T, Dusek L, Fínek J, Poprach A, Budnáková D, Kandrnal V, Jarkovský J, Bortlícek Z, Klimes D, Abrahámová J, Vyzula R.
    Klin Onkol; 2011 Aug 10; 24(5):389-92. PubMed ID: 22070021
    [Abstract] [Full Text] [Related]

  • 28. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, Gornadha Y, Elaidi R, Oudard S.
    Oncology; 2013 Aug 10; 85(1):8-13. PubMed ID: 23797151
    [Abstract] [Full Text] [Related]

  • 29. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M, Elaidi R, Brizard M, Fouque J, Takouchop C, Sabatier B, Oudard S, Medioni J.
    BMC Cancer; 2017 Jan 06; 17(1):27. PubMed ID: 28061764
    [Abstract] [Full Text] [Related]

  • 30. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.
    Eur Urol; 2011 Dec 06; 60(6):1163-70. PubMed ID: 21802830
    [Abstract] [Full Text] [Related]

  • 31. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B.
    J Clin Oncol; 2010 May 01; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract] [Full Text] [Related]

  • 32. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T, Mis L, Hammond JM.
    Ann Pharmacother; 2011 Jan 01; 45(1):78-83. PubMed ID: 21177421
    [Abstract] [Full Text] [Related]

  • 33. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
    Huelsmann L, Kim DNW, Hannan R, Watumull LM, Brugarolas J.
    Clin Genitourin Cancer; 2015 Aug 01; 13(4):e321-e323. PubMed ID: 25620636
    [No Abstract] [Full Text] [Related]

  • 34. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
    Czarnecka AM, Kornakiewicz A, Lian F, Szczylik C.
    Future Oncol; 2015 Aug 01; 11(5):801-17. PubMed ID: 25757683
    [Abstract] [Full Text] [Related]

  • 35. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 01; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
    Buchler T, Bortlicek Z, Poprach A, Kubackova K, Kiss I, Zemanova M, Fiala O, Dusek L, Vyzula R, Melichar B, Czech Renal Cancer Cooperative Group.
    Urol Oncol; 2014 Jul 01; 32(5):569-75. PubMed ID: 24629497
    [Abstract] [Full Text] [Related]

  • 37. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
    White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ.
    Am J Respir Crit Care Med; 2010 Aug 01; 182(3):396-403. PubMed ID: 20194812
    [Abstract] [Full Text] [Related]

  • 38. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
    Utsunomiya N, Kono Y, Matsumoto K, Matsumoto T, Nakagawa A, Tsunemori H, Okada T, Muguruma K, Kawakita M.
    Hinyokika Kiyo; 2014 Jan 01; 60(1):25-8. PubMed ID: 24594769
    [Abstract] [Full Text] [Related]

  • 39. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma.
    Saito Y, Nagayama M, Miura Y, Ogushi S, Suzuki Y, Noro R, Minegishi Y, Kimura G, Kondo Y, Gemma A.
    Jpn J Clin Oncol; 2013 May 01; 43(5):559-62. PubMed ID: 23423809
    [Abstract] [Full Text] [Related]

  • 40. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
    Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM, van der Vliet HJ.
    BMC Cancer; 2011 Nov 30; 11():505. PubMed ID: 22129044
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.